Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
April 25, 2024 08:30 ET
|
Elicio Therapeutics, Inc.
BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
April 05, 2024 16:30 ET
|
Elicio Therapeutics, Inc.
68% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD4+ T cells84% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD8+ T cellsThe majority of ELI-002-treated...
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
March 29, 2024 08:30 ET
|
Elicio Therapeutics, Inc.
ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024ELI-007 and ELI-008 preclinical data were accepted for a poster presentation at the AACR...
Elicio Therapeutics Announces $6.0 Million Private Placement Financing
March 18, 2024 08:00 ET
|
Elicio Therapeutics, Inc.
BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
March 06, 2024 08:30 ET
|
Elicio Therapeutics
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Elicio Therapeutics Completes Reverse Merger and Provides a Corporate Update
June 06, 2023 08:00 ET
|
Elicio Therapeutics
Elicio completes reverse merger, becoming a publicly traded company on the Nasdaq stock exchangePositive Phase 1 clinical data was recently presented at ASCO 2023 for the 2-peptide formulation of...
Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting
June 03, 2023 09:00 ET
|
Elicio Therapeutics
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndromeA high proportion of patients had tumor biomarker reduction (77%) with 32% having complete...
Elicio Therapeutics Reports Inducement Grant to New Chief Financial Officer
June 02, 2023 16:30 ET
|
Elicio Therapeutics
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today...
Elicio Therapeutics Announces Completion of Merger with Angion Biomedica
June 01, 2023 16:04 ET
|
Elicio Therapeutics
Shares of Elicio to commence trading on Nasdaq under the ticker symbol “ELTX” on June 2, 2023First in human Phase 1 data on lead candidate ELI-002 to be presented at 2023 American Society of Clinical...
Elicio Therapeutics to Present Interim Data from the Ongoing Phase 1 Study of Investigational Therapeutic Cancer Vaccine, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at ASCO
May 01, 2023 08:00 ET
|
Elicio Therapeutics
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases,...